Protara Therapeutics, Inc. Overview
Pro stress-test →Protara Therapeutics is a clinical-stage biotechnology company advancing transformative therapies for cancer and rare diseases, with its lead candidate TARA-002, an investigational cell-based therapy in development for non-muscle invasive bladder cancer and lymphatic malformations. The company recently demonstrated a 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancer.
Strategic Profile
Pro stress-test →Protara is evaluating TARA-002 in Phase 2 trials for NMIBC patients with carcinoma in situ who are unresponsive or naïve to BCG treatment, and in pediatric patients with lymphatic malformations. The company is also developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support.
Competitive Landscape
Pro stress-test →Protara competes in the rare disease and bladder cancer therapeutics space against other cell therapy and immunotherapy developers. Key competitors include other clinical-stage cell therapy platforms targeting similar indications, though TARA-002's localized cell therapy approach differentiates it from systemic immunotherapies and checkpoint inhibitors.
Industry Context
Protara Therapeutics, Inc. operates in Biopharmaceuticals / Clinical-Stage Therapeutics / Cell Therapy.
Key facts
Headquarters: New York, United States